{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:58:39Z","timestamp":1774983519646,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,31]]},"DOI":"10.7759\/cureus.106215","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:08:12Z","timestamp":1774980492000},"source":"Crossref","is-referenced-by-count":0,"title":["Understanding Hepatic Encephalopathy: Patient Knowledge, Adherence, and Barriers to Care in Cirrhosis"],"prefix":"10.7759","author":[{"given":"Noor","family":"Albusta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussain","family":"Alrahma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003641.07","article-title":"Considerations in the diagnosis and management of hepatic disease in older adults","volume":"120","author":"Brown CL","year":"2025","unstructured":"Brown CL, Bajaj JS. Considerations in the diagnosis and management of hepatic disease in older adults. Am J Gastroenterol. 2025, 120:S56-66. 10.14309\/ajg.0000000000003641.07","journal-title":"Am J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0267647","article-title":"Combination therapy with rifaximin and lactulose in hepatic encephalopathy: a systematic review and meta-analysis","volume":"17","author":"Fu J","year":"2022","unstructured":"Fu J, Gao Y, Shi L. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: a systematic review and meta-analysis. PLoS One. 2022, 17:e0267647. 10.1371\/journal.pone.0267647","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011585.pub2","article-title":"Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis","volume":"7","author":"Zacharias HD","year":"2023","unstructured":"Zacharias HD, Kamel F, Tan J, Kimer N, Gluud LL, Morgan MY. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2023, 7:CD011585. 10.1002\/14651858.CD011585.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.5997","article-title":"Diagnosis and management of cirrhosis and its complications: a review","volume":"329","author":"Tapper EB","year":"2023","unstructured":"Tapper EB, Parikh ND. Diagnosis and management of cirrhosis and its complications: a review. JAMA. 2023, 329:1589-602. 10.1001\/jama.2023.5997","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-07935-z","article-title":"Barriers to lactulose adherence in patients with cirrhosis and hepatic encephalopathy","volume":"68","author":"Chow KW","year":"2023","unstructured":"Chow KW, Ibrahim BM, Yum JJ, et al.. Barriers to lactulose adherence in patients with cirrhosis and hepatic encephalopathy. Dig Dis Sci. 2023, 68:2389-97. 10.1007\/s10620-023-07935-z","journal-title":"Dig Dis Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1600561","article-title":"Hepatic encephalopathy","volume":"375","author":"Wijdicks EF","year":"2016","unstructured":"Wijdicks EF. Hepatic encephalopathy. N Engl J Med. 2016, 375:1660-70. 10.1056\/NEJMra1600561","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2021.06.007","article-title":"Overt hepatic encephalopathy: current pharmacologic treatments and improving clinical outcomes","volume":"134","author":"Rahimi RS","year":"2021","unstructured":"Rahimi RS, Brown KA, Flamm SL, Brown RS Jr. Overt hepatic encephalopathy: current pharmacologic treatments and improving clinical outcomes. Am J Med. 2021, 134:1330-8. 10.1016\/j.amjmed.2021.06.007","journal-title":"Am J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003899","article-title":"ACG clinical guideline: hepatic encephalopathy","volume":"121","author":"Bajaj JS","year":"2026","unstructured":"Bajaj JS, Jakab SS, Jesudian AB, et al.. ACG clinical guideline: hepatic encephalopathy. Am J Gastroenterol. 2026, 121:588-618. 10.14309\/ajg.0000000000003899","journal-title":"Am J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019603","article-title":"A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy","volume":"99","author":"Vadhariya A","year":"2020","unstructured":"Vadhariya A, Chen H, Serna O, Zamil H, Abughosh SM. A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy. Medicine (Baltimore). 2020, 99:e19603. 10.1097\/MD.0000000000019603","journal-title":"Medicine (Baltimore)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13892","article-title":"Optimizing medication management for patients with cirrhosis: evidence-based strategies and their outcomes","volume":"38","author":"Thomson MJ","year":"2018","unstructured":"Thomson MJ, Lok AS, Tapper EB. Optimizing medication management for patients with cirrhosis: evidence-based strategies and their outcomes. Liver Int. 2018, 38:1882-90. 10.1111\/liv.13892","journal-title":"Liver Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.08.025","article-title":"Measuring medication use, obstacles, and knowledge in individuals with cirrhosis","volume":"21","author":"Desai AP","year":"2023","unstructured":"Desai AP, Duzdar S, Stump T, et al.. Measuring medication use, obstacles, and knowledge in individuals with cirrhosis. Clin Gastroenterol Hepatol. 2023, 21:1819-1830.e5. 10.1016\/j.cgh.2022.08.025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup H","year":"2014","unstructured":"Vilstrup H, Amodio P, Bajaj J, et al.. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014, 60:715-35. 10.1002\/hep.27210","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23216","article-title":"Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy","volume":"50","author":"Bajaj JS","year":"2009","unstructured":"Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology. 2009, 50:2014-21. 10.1002\/hep.23216","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08704-2","article-title":"Multimedia-based education led to improvement in disease knowledge among patients with cirrhosis","volume":"69","author":"Verma M","year":"2024","unstructured":"Verma M, Chan M, Toroghi S, Gallagher M, Lo K, Navarro V. Multimedia-based education led to improvement in disease knowledge among patients with cirrhosis. Dig Dis Sci. 2024, 69:4364-72. 10.1007\/s10620-024-08704-2","journal-title":"Dig Dis Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gin\u00e8s P","year":"2021","unstructured":"Gin\u00e8s P, Krag A, Abraldes JG, Sola E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021, 398:1359-76. 10.1016\/S0140-6736(21)01374-X","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/477717-understanding-hepatic-encephalopathy-patient-knowledge-adherence-and-barriers-to-care-in-cirrhosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T18:08:13Z","timestamp":1774980493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/477717-understanding-hepatic-encephalopathy-patient-knowledge-adherence-and-barriers-to-care-in-cirrhosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.106215","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,31]]}}}